What the FDA proposed and why

The 503B pathway allows FDA-registered outsourcing facilities to compound drugs in bulk for distribution to healthcare facilities without patient-specific prescriptions — a model that enabled the GLP-1 compounding industry to reach the scale it achieved from 2022 to 2025. The FDA’s authority to allow bulk compounding under 503B is conditional: it applies only when there is a clinical need that cannot be met by commercially manufactured alternatives. FDA’s position in the April 30 proposal is that approved GLP-1 products (Ozempic, Wegovy, Mounjaro, Zepbound) are commercially available, and that therefore no 503B clinical need exists — regardless of prior shortage designations. The exclusion is permanent by design: a future shortage designation would not re-open the 503B bulk compounding door once the exclusion rule is finalised.

This is a structural change rather than a shortage-response measure. The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, triggering immediate enforcement. The proposed 503B exclusion is the legal mechanism to prevent the pattern from repeating — the back-and-forth of shortage designation opening compounding and shortage resolution triggering enforcement that characterised 2025. The three drugs named in the proposal — semaglutide, tirzepatide, liraglutide — account for the substantial majority of the 503B GLP-1 compounding market by volume.

The comment period: 3,901 submissions by July 30

The public comment period ran from April 30 to July 30, 2026 — 91 days rather than the standard 60, reflecting the agency’s acknowledgement of the public interest in the proceeding. By the July 30 deadline, 3,901 comments had been submitted to the Federal Register docket. This is a meaningful volume for a pharmaceutical compounding rulemaking, where most proceedings receive dozens to low hundreds of substantive submissions. For context, the FDA’s 2014 proposal to establish the 503B category itself generated substantially fewer comments in its first round.

The comment composition matters for the final rule timeline. The FDA is required under the Administrative Procedure Act to read and formally respond to every substantive comment in the final rule document. Comments that raise factual claims, cite contradictory scientific evidence, or identify procedural deficiencies require the most extensive response. If the 3,901 submissions include a large proportion of substantive scientific or legal arguments — which is likely given the organised opposition from compounding pharmacy associations, patient advocacy groups, and telehealth platforms — the review process is estimated to take 6–18 months beyond the close of the comment period. A final rule before mid-2027 is possible but requires prioritisation. A 2027–2028 timeline is the more conservative planning assumption.

The Fifth Circuit ruling: August 27, 2026

On August 27, 2026, the Fifth Circuit Court of Appeals affirmed the FDA’s authority to restrict GLP-1 compounding under the 503B shortage framework. The ruling addressed a challenge brought by a coalition of compounding pharmacy operators arguing that the FDA had exceeded its statutory authority in enforcing the shortage resolution determinations that triggered the compounding crackdown. The Fifth Circuit’s majority held that the FDA’s shortage determination process was within the bounds of its FD&C Act authority and that the enforcement actions that followed were consistent with the agency’s statutory mandate.

The legal significance of this ruling for the 503B exclusion proceeding is that it removes the most viable judicial avenue for challenging the rulemaking before finalisation. Prior to the Fifth Circuit decision, compounding industry challengers had a viable argument that the agency’s shortage determinations were arbitrary and therefore that the enforcement actions derived from them lacked legal foundation. The Fifth Circuit’s affirmation of FDA’s shortage determination authority substantially narrows that argument. Post-comment litigation to block the final exclusion rule is still legally possible — on APA procedural grounds, or if the final rule deviates materially from the proposed rule without adequate explanation — but the pharmaceutical compounding industry’s strongest pre-finalisation judicial card has now been played and lost.

The 503A alternative: what remains legal and under what conditions

The 503B exclusion proposal does not target the 503A compounding pathway. Under 503A, individual state-licensed compounding pharmacies can prepare semaglutide or tirzepatide for a specific identified patient under a valid prescription from a licensed prescriber, using an FDA-registered bulk API with a Certificate of Analysis, provided no commercially manufactured equivalent is available in the form required for that patient. The “no commercially available equivalent” standard is where legal complexity concentrates: with Ozempic, Wegovy, Mounjaro, and Zepbound commercially available, the threshold for demonstrating medical necessity for the compounded form is high.

The 503A pathway is further under pressure from a different direction: more than 40 state attorneys general have opened investigations into telehealth platforms that were using 503A compounders as a de facto commercial distribution channel — pre-compounding vials, shipping nationally, and operating at volumes inconsistent with the patient-specific model that 503A requires. Several of these investigations resulted in platform shutdowns and licensing actions in mid-2026. The 503A channel that existed at scale from 2023 to 2025 is not legally replicable under current enforcement posture without genuine patient-specific prescription architecture and demonstrated medical necessity for the compounded form.

The warning letter enforcement record

The FDA has issued more than 100 warning letters to telehealth companies and compounders since the semaglutide shortage was resolved in February 2025 — 25 in the week of June 15, 2026 alone. The enforcement theory is consistent across letters: marketing that implies a compounded GLP-1 is FDA-approved, equivalent to an approved drug, or appropriate for general commercial distribution triggers the letter regardless of whether the underlying compounding act was itself technically permissible under 503A. The letters have had material commercial impact: Peptide Sciences, which had an estimated 990,000 monthly website visits, shut down March 6, 2026. At least eight major vendors have closed since mid-2025, many citing enforcement risk rather than direct regulatory action against them specifically.

Where the proceeding stands as of September 2026

What this means for the research community

The GLP-1 compounding landscape as it existed from 2022 to 2025 is not returning. The legal, enforcement, and judicial architecture is now comprehensive: a proposed exclusion rule with record comment volume moving toward finalisation, a Fifth Circuit affirmation of FDA’s authority, an active warning letter programme, and state AG enforcement targeting the telehealth distribution model. Researchers who incorporated compounded semaglutide or tirzepatide into protocols need to plan around the branded drug channel, patient assistance programmes, or international sourcing frameworks, depending on their specific context.

The July 23–24, 2026 PCAC vote — which produced positive recommendations for BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon for 503A listing — represents the constructive counterpoint to the GLP-1 enforcement story. A tightening of the GLP-1 compounding space is occurring simultaneously with the opening of a formal legal pathway for the core research peptides. The two proceedings are distinct in law and in the compounds involved, but together they define the regulatory trajectory: the FDA is closing the GLP-1 compounding channel while beginning to formalise access to the peptide category that the research community has used alongside it. For the full rulemaking timeline from PCAC vote to legal 503A compounding, see our PCAC rulemaking explainer.

---

Editorial Note: This article is published for research and educational purposes only. Peptide Hub does not sell peptides, receive commissions from peptide vendors, or endorse any specific supplier. All content is for educational reference only and does not constitute medical or legal advice.

Sources

1. FDA — Proposed rule: Semaglutide, tirzepatide, liraglutide exclusion from 503B bulks list (April 30, 2026): fda.gov
2. Orrick — FDA moves to shut the door on large-scale compounding of GLP-1 drugs (May 2026): orrick.com
3. Pharmacy Times — FDA moves to permanently close the door on compounded GLP-1s: pharmacytimes.com
4. BioPharma Dive — FDA moves toward easing restrictions on certain peptides: biopharmadive.com
5. Fifth Circuit — Affirmation of FDA GLP-1 compounding restriction authority (August 27, 2026): Reported by NPR and RAPS
6. FDA — Section 503B outsourcing facility overview: fda.gov
7. Drug Topics — GLP-1 no longer on FDA's drug shortage list: drugtopics.com